Nordic Nanovector Announces that the data from the LYMRIT 37-05 Phase 1 Trial of Betalutin in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) will be presented at EHA 2022 Meeting
OSLO, Norway, June 10, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces an update from the LYMRIT 37-05 Phase 1 trial investigating Betalutin (177Lu lilotomab satetraxetan)
Gomez Codina Erik Skullerud Malene Brondberg Frazer Hall Medi European Hematology Association Nordic Nanovector
Source: finanznachrichten.de